Three-drug combo improves lung function in most common genetic form of cystic fibrosis.

[2greys]

A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a single copy of the most common genetic mutation for the disease.

Earlier this month, the Food and Drug Administration approved the therapy based on the results of this international study, published today in the New England Journal of Medicine. A companion investigation appearing simultaneously in The Lancet reported on people with one or two copies of the mutation.

utsouthwestern.edu/newsroom...

[Cateran]

well-spotted 2greys. CF is such a blight on life expectancy that any breakthrough such as Raksha Jain's team is very promising.The combination drug therapy is quite a mouthful to write out yet the results are encouraging for young participants. Gene research is so vital despite ethical objections in some quarters of zealotry. This breakthrough highlights this truth. Science matters.